Tocilizumab，一种抗人IL-6R的人源化抗体，能够靶向人白细胞介素-6受体（IL-6R），阻断IL-6与IL-6R的结合，从而抑制经典信号通路和反式信号通路，可用于类风湿关节炎的相关研究。
Purity:SDS-PAGE
Anti-IL-6Ra / CD126 Reference Antibody (tocilizumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
Purity:SEC-HPLC
The purity of Anti-IL-6Ra / CD126 Reference Antibody (tocilizumab) is more than 95%, determined by SEC-HPLC.
Bioactivity:FACS
Human IL-6R CHOs cells were stained with Anti-IL-6Ra / CD126 Reference Antibody (tocilizumab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC50=0.4525 nM.
Function:Blocking
Anti-IL-6Ra / CD126 Reference Antibody (tocilizumab)-induced FACS Blocking activity was evaluated using Human IL-6R CHO cells. The IC50 was approximately 1.303nM.
-25~-15℃保存，有效期1年。
